482 related articles for article (PubMed ID: 29445943)
1. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.
Honjo M; Tanihara H
Jpn J Ophthalmol; 2018 Mar; 62(2):109-126. PubMed ID: 29445943
[TBL] [Abstract][Full Text] [Related]
2. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
Inoue T; Tanihara H
Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
[TBL] [Abstract][Full Text] [Related]
3. Rho-associated kinase inhibitors: a novel glaucoma therapy.
Inoue T; Tanihara H
Prog Retin Eye Res; 2013 Nov; 37():1-12. PubMed ID: 23770081
[TBL] [Abstract][Full Text] [Related]
4. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.
Rao PV; Pattabiraman PP; Kopczynski C
Exp Eye Res; 2017 May; 158():23-32. PubMed ID: 27593914
[TBL] [Abstract][Full Text] [Related]
5. Ripasudil: first global approval.
Garnock-Jones KP
Drugs; 2014 Dec; 74(18):2211-5. PubMed ID: 25414122
[TBL] [Abstract][Full Text] [Related]
6. Interaction Between Pilocarpine and Ripasudil on Intraocular Pressure, Pupil Diameter, and the Aqueous-Outflow Pathway.
Yamagishi-Kimura R; Honjo M; Komizo T; Ono T; Yagi A; Lee J; Miyata K; Fujimoto T; Inoue T; Tanihara H; Nishida J; Uchida T; Araki Y; Aihara M
Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1844-1854. PubMed ID: 29677344
[TBL] [Abstract][Full Text] [Related]
7. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
Komizo T; Ono T; Yagi A; Miyata K; Aihara M
Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
[TBL] [Abstract][Full Text] [Related]
8. Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy.
Jethva J; Bhagat P; Prajapati K; Tank G
Indian J Ophthalmol; 2022 Jun; 70(6):2020-2023. PubMed ID: 35647972
[TBL] [Abstract][Full Text] [Related]
9. Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.
Tanna AP; Johnson M
Ophthalmology; 2018 Nov; 125(11):1741-1756. PubMed ID: 30007591
[TBL] [Abstract][Full Text] [Related]
10. Rho-kinase inhibitors in the management of glaucoma.
Berrino E; Supuran CT
Expert Opin Ther Pat; 2019 Oct; 29(10):817-827. PubMed ID: 31573364
[No Abstract] [Full Text] [Related]
11. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells.
Kaneko Y; Ohta M; Inoue T; Mizuno K; Isobe T; Tanabe S; Tanihara H
Sci Rep; 2016 Jan; 6():19640. PubMed ID: 26782355
[TBL] [Abstract][Full Text] [Related]
12. Rho/Rho-associated kinase pathway in glaucoma (Review).
Wang J; Liu X; Zhong Y
Int J Oncol; 2013 Nov; 43(5):1357-67. PubMed ID: 24042317
[TBL] [Abstract][Full Text] [Related]
13. An update on ripasudil for the treatment of glaucoma and ocular hypertension.
Testa V; Ferro Desideri L; Della Giustina P; Traverso CE; Iester M
Drugs Today (Barc); 2020 Sep; 56(9):599-608. PubMed ID: 33025953
[TBL] [Abstract][Full Text] [Related]
14. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits.
Isobe T; Mizuno K; Kaneko Y; Ohta M; Koide T; Tanabe S
Curr Eye Res; 2014 Aug; 39(8):813-22. PubMed ID: 24502505
[TBL] [Abstract][Full Text] [Related]
15. Rho kinase inhibitors for glaucoma treatment - Review.
Germano RA; Finzi S; Challa P; Susanna Junior R
Arq Bras Oftalmol; 2015; 78(6):388-91. PubMed ID: 26677046
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy.
Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
J Glaucoma; 2017 Feb; 26(2):96-100. PubMed ID: 27661993
[TBL] [Abstract][Full Text] [Related]
17. A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
Hsu CR; Chen YH; Liu CP; Chen CH; Huang KK; Huang JW; Lin MN; Lin CL; Chen WR; Hsu YL; Lee TC; Chou SH; Tu CM; Hwang CS; Huang YC; Lu DW
Invest Ophthalmol Vis Sci; 2019 Feb; 60(2):624-633. PubMed ID: 30735565
[TBL] [Abstract][Full Text] [Related]
18. [The possibility of selective Rho-associated kinase (ROCK) inhibitors as a medical treatment for glaucoma].
Honjo M
Nippon Ganka Gakkai Zasshi; 2009 Nov; 113(11):1071-81. PubMed ID: 19994585
[TBL] [Abstract][Full Text] [Related]
19. Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.
Lu LJ; Tsai JC; Liu J
Yale J Biol Med; 2017 Mar; 90(1):111-118. PubMed ID: 28356898
[TBL] [Abstract][Full Text] [Related]
20. Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study.
Futakuchi A; Morimoto T; Ikeda Y; Tanihara H; Inoue T;
Sci Rep; 2020 Jun; 10(1):10308. PubMed ID: 32587304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
